Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia

Journal of Medical Economics

Volumn 16, Issue 8, 2013, Pages 997-1006

  Lang, Kathleen ^a   Federico, Victoria ^a   Muser, Erik ^b   Menzin, Jordan ^a   Menzin, Joseph ^a  

^a Boston Health Economics Inc   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adherence; Antipsychotics; Hospitalization; Non adherence; Predictors; Risk; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER;

ADULT; ARTICLE; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTHCARE COMMON PROCEDURE CODING SYSTEM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRESCRIPTION; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT REFUSAL;

ADULT; ANTIPSYCHOTIC AGENTS; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84880557005     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.816310     Document Type: Article

References (20)

1. National Institute of Mental Health. Schizophrenia. Bethesda, MD: National Institutes of Health, 2009. http://www.nimh.nih.gov/health/topics/ schizophrenia/index.shtml. Accessed April 6, 2009
2. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
3. Lang K, Meyers JL, Korn JR, et al. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv 2010;61:1239-47
4. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 2005;23:3-21
5. Perkins D. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2006;63:1121-8
6. Gilmer TP, Dolder CR, Larco J, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
7. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005;6:129-37
8. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11
9. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-9
10. Gianfrancesco F, Rajagopalan KS, Sajatovic M, et al. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 2006;144:177-89
11. Becker MA, Young MS, Ochshom E, et al. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm Policy Mental Health 2007;34:307-14
12. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004;30:255-64
13. Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004;55:997-1005
14. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
15. Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
16. Karve S, Cleves MA, Helm M, et al. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009;12:989-95
17. Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008;69:47-53
18. Khaykin E, Eaton WW, Ford DE, et al. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv 2010;61:830-4
19. Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013;16:231-9
20. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;53:323-37